196 related articles for article (PubMed ID: 27366017)
41. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
42. Pralatrexate (Folotyn) for peripheral T-cell lymphoma.
Med Lett Drugs Ther; 2010 Jul; 52(1342):55-6. PubMed ID: 20622807
[No Abstract] [Full Text] [Related]
43. Pralatrexate, a new hope for aggressive T-cell lymphomas?
Rueda A; Casanova M; Quero C; Medina-Pérez A
Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis.
Zhu J; Yeoh EM; Maeda Y; Tobinai K
Leuk Lymphoma; 2020 Sep; 61(9):2145-2152. PubMed ID: 32536233
[TBL] [Abstract][Full Text] [Related]
45. FDA approves pralatrexate for treatment of rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2009 Nov; 66(21):1890. PubMed ID: 19850775
[No Abstract] [Full Text] [Related]
46. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
O'Connor OA; Hamlin PA; Portlock C; Moskowitz CH; Noy A; Straus DJ; Macgregor-Cortelli B; Neylon E; Sarasohn D; Dumetrescu O; Mould DR; Fleischer M; Zelenetz AD; Sirotnak F; Horwitz S
Br J Haematol; 2007 Nov; 139(3):425-8. PubMed ID: 17910632
[TBL] [Abstract][Full Text] [Related]
47. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
[TBL] [Abstract][Full Text] [Related]
48. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
49. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
50. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Broccoli A; Argnani L; Zinzani PL
Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
[TBL] [Abstract][Full Text] [Related]
51. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Marchi E; Paoluzzi L; Scotto L; Seshan VE; Zain JM; Zinzani PL; O'Connor OA
Clin Cancer Res; 2010 Jul; 16(14):3648-58. PubMed ID: 20501616
[TBL] [Abstract][Full Text] [Related]
52. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
53. Pralatrexate - from bench to bedside.
Zain JM; Marchi E
Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
[TBL] [Abstract][Full Text] [Related]
54. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
Ong SY; Phipps C; Kaur H; Tan L; Lee YS
Ann Acad Med Singap; 2019 Sep; 48(9):298-300. PubMed ID: 31737895
[No Abstract] [Full Text] [Related]
55. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
[TBL] [Abstract][Full Text] [Related]
56. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
Koch E; Story SK; Geskin LJ
Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
[TBL] [Abstract][Full Text] [Related]
57. Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.
Iyer SP; Johnston PB; Barta SK
Blood Adv; 2024 Jan; 8(2):353-364. PubMed ID: 38029357
[TBL] [Abstract][Full Text] [Related]
58. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
Altınay S; Kural A; Özmen A; Tural D; Tutar Y
Anticancer Agents Med Chem; 2023; 23(3):298-305. PubMed ID: 35692151
[TBL] [Abstract][Full Text] [Related]
59. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma.
Ishitsuka K; Utsunomiya A; Katsuya H; Takeuchi S; Takatsuka Y; Hidaka M; Sakai T; Yoshimitsu M; Ishida T; Tamura K
Cancer Sci; 2015 Sep; 106(9):1219-23. PubMed ID: 26179770
[TBL] [Abstract][Full Text] [Related]
60. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]